Cryptococcosis

Infectious Disease Clinics of North America

Volumn 16, Issue 4, 2002, Pages 837-874

  Perfect, John R ^a   Casadevall, Arturo ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; POSACONAZOLE; VORICONAZOLE;

CLINICAL FEATURE; CLINICAL TRIAL; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DIAGNOSTIC APPROACH ROUTE; EVOLUTION; FUNGAL MENINGITIS; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; IMMUNITY; IMMUNOMODULATION; MOLECULAR GENETICS; OPPORTUNISTIC INFECTION; PROGNOSIS; REVIEW; SIDE EFFECT; VIRULENCE;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; CENTRAL NERVOUS SYSTEM FUNGAL INFECTIONS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DERMATOMYCOSES; DISEASE MANAGEMENT; EYE INFECTIONS, FUNGAL; HUMANS; IMMUNITY, CELLULAR; INCIDENCE; MALE; MENINGITIS, CRYPTOCOCCAL; MICE; PROGNOSIS; PROSTATE; RISK FACTORS;

EID: 0036902902     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(02)00036-3     Document Type: Review

References (280)

1. Ikeda R, Shinoda T, Fukuzawa Y, Kaufman L. Antigenic characterization of Cryptococcus neoformans serotypes and its application to serotyping of clinical isolates. J Clin Microbiol 1982;36:22-9.
2. Dromer F, Gueho E, Ronin O, Dupont B. Serotyping of Cryptococcus neoformans by using a monoclonal antibody specific for capsular polysaccharide. J Clin Microbiol 1993;31:359-63.
3. Cleare W, Casadevall A. The different binding patterns of two IgM monoclonal antibodies to Cryptococcus neoformans serotype A and D strains correlates with serotype classification and differences in functional assays. Clin Diagn Lab Immunol 1998;5:125-9.
4. Franzot SP, Salkin IF, Casadevall A. Cryptococcus neoformans var. grubii: Separate variety status for Cryptococcus neoformans serotype A isolates. J Clin Microbiol 1999;37:838-40.
5. Boekhout T, Theelen B, Diaz M. Hybrid genotypes in the pathogenic yeast Cryptococcus neoformans. Microbiology 2001;147:891-907.
6. Bennett JE, Kwon-Chung KJ, Howard DH. Epidemiology differences among serotypes of Cryptococcus neoformans. Am J Epidemiol 1977;105:582.
7. Kwon-Chung KJ, Bennett JE. Epidemiologic differences between the two varieties of Cryptococcus neoformans. Am J Epidemiol 1984;120:123-40.
8. Steenbergen JN, Casadevall A. Prevalence of Cryptococcus neoformans var neoformans (serotype D) and Cryptococcus neoformans var. grubii (serotype A) isolates in New York City. J Clin Microbiol 2000;38:1974-6.
9. Chen S, Sorrell T, Nimmo G. Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Clin Infect Dis 2000;31:499-508.
10. Dromer F, Mathoulin S, Dupont B, Letenneur L, Ronin O. Individual and environmental factors associated with infection due to Cryptococcus neoformans serotype D. Clin Infect Dis 1996;23:91-6.
11. Baker RD. The primary pulmonary lymph node complex of cryptococcosis. Am J Clin Pathol 1976;65:83-92.
12. Haugen RK, Baker RD. The pulmonary lesions in cryptococcosis with special reference to subpleural nodule. J Clin Pathol 1954;24:1381.
13. Salyer WR, Salyer DC, Baker RD. Primary complex of Cryptococcus and pulmonary lymph nodes. J Infect Dis 1974;130:74-7.
14. Garcia-Hermoso D, Janbon G, Dromer F. Epidemiological evidence for dormant Cryptococcus neoformans infection. J Clin Microbiol 1999;37:3204-9.
15. Dromer F, Ronin O, Dupont B. Isolation of Cryptococcus neoformans var. gattii from an Asian patient in France: Evidence for dormant infection in healthy subjects. J Med Vet Mycol 1992;30:395-7.
16. Fessel WJ. Cryptococcal meningitis after unusual exposures to birds. N Engl J Med 1993;328:1354-5.
17. Nosanchuk JD, Shoham S, Fries BC. Evidence for zoonotic transmission of Cryptococcus neoformans from a pet cockatoo to an immunocompromised patient. Ann Intern Med 2000;132:205-8.
18. Schimpff SC, Bennett JE. Abnormalities in cell-mediated immunity in patients with Cryptococcus neoformans infection. J Allergy Clin Immunol 1975;55:430-41.
19. Newberry Jr. WM, Walter JE, Chandler Jr. JW, Tosh FE. Epidemiologic study of Cryptococcus neoformans. Ann Intern Med 1967;67:724-32.
20. Chen L-C, Goldman DL, Doering TL. Antibody response to Cryptococcus neoformans proteins in rodents and humans. Infect Immunol 1999;67:2218-24.
21. Goldman DL, Khine H, Abadi J. Serologic evidence for cryptococcus infection in early childhood. Pediatrics 2001;107:66.
22. Howard DH. The commensalism of Cryptococcus neoformans. Sabouraudia 1973;11: 171-4.
23. Randhawa HS, Paliwal DK. Occurrence and significance of Cryptococcus neoformans in the oropharynx and on the skin of a healthy human population. J Clin Microbiol 1977;6:325-7.
24. Randhawa HS, Pal M. Occurrence and significance of Cryptococcus neoformans in the respiratory tract of patients with bronchopulmonary disorders. J Clin Microbiol 1977;5:5-8.
25. Tynes B, Mason KN, Jennings AE, Bennett JE. Variant forms of pulmonary cryptococcosis. Ann Intern Med 1968;69:1117-25.
26. Friedman GD. The rarity of cryptococcosis in Northern California: The 10-year experience of a large defined population. Am J Epidemiol 1983;117:230-4.
27. Kaufman L, Blumer S. Cryptococcosis: the awakening giant. Proceedings of the Fourth International Conference on the Mycoses. Pan-American Health Organization 1977;356:176-82.
28. Hajjman A, Conn LA, Stephens DS. Cryptococcosis: Population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group. J Infect Dis 1999;179:449-54.
29. Thomas CJ, Lee JY, Conn LA. Surveillance of cryptococcosis in Alabama, 1992-1993. Ann Epidemiol 1998;8:212-6.
30. Hajjeh RA, Brandt ME, Pinner RW. Emergency of cryptococcal disease: Epidemiologic perspective 100 years after its discovery. Epidemiol Rev 1995;17:303-20.
31. Kovacs JA, Kovacs AA, Polis M, Wright WC, Gill VJ, Tuazon CU, et al. Cryptococcosis in the acquired immunodeficiency syndrome. Ann Intern Med 1985;103:533-8.
32. Zuger A, Louie E, Holzman RS, Simberkoff MS, Rahal JJ. Cryptococcal disease in patients with acquired immunodeficiency syndrome: Diagnostic features and outcome of treatment. Ann Intern Med 1986;104:234-40.
33. Eng RHK, Bishburg E, Smith SM. Bacteremia and fungemia in patients with the acquired immune deficiency syndrome. Am J Clin Pathol 1986;86:105-7.
34. Chuck SL, Sande MA. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med 1989;321:794-9.
35. Clark RA, Greer D, Atkinson W, Valainis GT, Hyslop N. Spectrum of Cryptococcus neoformans infection in 68 patients infected with acquired immunodeficiency virus. Rev Infect Dis 1990;12:768-77.
36. Currie BP, Casadevall A. Estimation of the prevalence of cryptococcal infection among HIV-infected individuals in New York City. Clin Infect Dis 1994;19:1029-33.
37. Sorvillo F, Beall G. Turner PA. Incidence and factors associated with extrapulmonary cryptococcosis among persons with HIV infection in Los Angeles County. AIDS 1997;11:673-9.
38. Collins VP, Gellhorn A, Trimble JR. The coincidence of cryptococcosis and disease of the reticulo-endothelial and lymphatic systems. Cancer 1995;4:883-9.
39. Zimmerman LE, Rappaport H. Occurrence of cryptococcosis in patients with malignant disease of reticuloendothelial system. Am J Clin Pathol 1954;24:1050.
40. Kaplan MH, Rosen PP, Armstrong D. Cryptococcus in a cancer hospital: Clinical and pathological correlates in forty-six patients. Cancer 1977;39:2265-74.
41. Hutter RVP, Collins HS. The occurrence of opportunistic fungus infections in a cancer hospital. Lab Invest 1962;11:1035-45.
42. Kontoyiannis DP, Peitsch WK, Reddy BT. Cryptococcosis in patients with cancer. Clin Infect Dis 2001;32:145-50.
43. Husain A, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: Variables influencing clinical characteristics and outcome. Emerg Infect Dis 2001;7:375-81.
44. Beyt BE, Waltman SR. Cryptococcal endophthalmitis after corneal transplantation. N Engl J Med 1978;298:825-6.
45. Kanj SS, Welty-Wolf K, Madden J, Tapson V, Baz MA, Davis RD, et al. Fungal infections in lung and heart-lung transplant recipients, report of 9 cases and review of the literature. Medicine (Baltimore) 1996;75:142-56.
46. Casadevall A, Perfect JR. Cryptococcus Neoformans. Washington: ASM Press; 1998.
47. Powell KE, Dahl BA, Weeks RJ, Tosh FE. Airborne Cryptococcus neoformans: Particles from pigeon excreta compatible with alveolar deposition. J Infect Dis 1972;126:412-5.
48. Neilson JB, Fromtling RA, Bulmer GS. Cryptococcus neoformans: Size range of infectious particles from aerosolized soil. Infect Immunol 1977;17:634-8.
49. Ruiz A, Bulmer GS. Particle size of airborne Cryptococcus neoformans in a tower. Appl Environ Microbiol 1980;41:1225-9.
50. Sorrell TC, Chen S, Ruma P, Meyer N, Pfeiffer TJ, Ellis DH, et al. Concordance of clinical and environmental isolates of Cryptococcus neoformans var. gattii by random amplification of polymorphic DNA analysis and PCR fingerprinting. J Clin Microbiol 1996;34:1253-60.
51. Currie BP, Freundlich LF, Casadevall A. Restriction fragment length polymorphism analysis of Cryptococcus neoformans isolates from environmental (pigeon excreta) and clinical sources in New York City. J Clin Microbiol 1994;32:1188-92.
52. Yamamoto Y, Kohno S, Koga H, Kakeya H, Tomono K, Kaku M, et al. Random amplified polymorphic DNA analysis of clinically and environmentally isolated Cryptococcus neoformans in Nagasaki. J Clin Microbiol 1995;33:3328-32.
53. Chariyalertsak S, Sirisanthana T, Supparatpinyo K, Nelso KE. Seasonal variation of disseminated Penicillium marneffei infections in northern Thailand: A clue to the reservoir? J Infect Dis 1996;173:1490-3.
54. Goldstein E, Rombo ON. Cryptococcal infection following steroid therapy. Ann Intern Med 1962;56:114.
55. Gallis HA, Berman RA, Cate TR. Fungal infection following renal transplantation. Arch Intern Med 1975;135:1163-72.
56. Iseki M, Anzo M, Yamashita N, Matsuo N. Hyper-IgM immunodeficiency with disseminated cryptococcosis. Acta Paediatr 1994;83:780-2.
57. Kyong CU, Virella G, Fudenberg HH, Darby CP. X-linked immunodeficiency with increased IgM: Clinical, ethnic, and immunologic heterogeneity. Pediatr Res 1978;12:1024-6.
58. Tabone MD, Leverger G, Landman J, Asnar C, Boccon-Gibod L, Lasfargues G. Disseminated lymphonodular cryptococcosis in a child with x-linked hyper-IgM immunodeficiency. Pediatr Infect Dis J 1994;13:77-9.
59. Dev D, Basran GS, Slater D. Consider HIV negative immunodeficiency in cryptococcosis. BMJ 1994;308:1436.
60. Olson PE, Earhart KC, Rossetti RJ. Smoking and risk of cryptococcosis in patients with AIDS. JAMA 1997;277:629.
61. Crowe SM, Carlin JB, Stewart KI, Lucas CR, Hoy JF. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J Acquir Immune Defic Syndr Hum Retrovirol 1991;4:770-6.
62. Bacellar H, Munoz A, Miller EN. Temporal trends in the incidence of HIV-1-related neurologic diseases. Neurology 1994;44:1892-900.
63. McNeill JI, Kan VL. Decline in the incidence of cryptococcosis among HIV-related patients. J Acquir Immune Defic Syndr Hum Retrovirol 1995;206:207.
64. van Elden LJ, Walenkamp AM, Lipovsky MM. Declining number of patients with cryptococcosis in The Netherlands in the era of highly active antiretroviral therapy. AIDS 2000;14:2787-8.
65. Newton JA, Tasker SA, Bone WD, Oldfield EC, Olson PE, Nguyen MT, et al. Weekly fluconazole for the suppression of recurrent thrush in HIV seropositive patients: Impact on the incidence of disseminated cryptococcal infection. AIDS 1995;9:1286-7.
66. Ammasari A, Linzalone A, Murr R, Marasea G, Morace G, Antinori A. Fluconazole for prophylaxis of AIDS-associated cryptococcosis: A case-control study. Scand J Infect Dis 1995;27:235-7.
67. Powderly WG, Finkelstein DM, Feinberg J, Frame P, He W, van der Horst C, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995;332:700-5.
68. Archibald LK, McDonald LC, Rheanpumikankit S. Fever and human immunodeficiency virus infection as sentinels for emerging mycobacterial and fungal bloodstream infections in hospitalized patients > 15 years old. Bangkok J Infect Dis 1999;180:87-92.
69. Gordon SB, Walsh AL, Chaponda M. Bacterial meningitis in Malawian adults: Pneumococcal disease is common, severe, and seasonal. Clin Infect Dis 2000;31:53-7.
70. Clumeck N, Sonnet J, Taelman H, Mascart-Lemone F, De Bruyere M, Vandeperre P, et al. Acquired immunodeficiency syndrome in African patients. N Engl J Med 1984; 310:492-7.
71. Van de Perre P, Lepage P, Kestelyn P. Acquired immunodeficiency syndrome in Rwanda. Lancet 1984;2:62-5.
72. Hakim JG, Gangaidzo IT, Heyderman RS. Impact of HIV infection on meningitis in Harare, Zimbabwe: A prospective study of 406 predominantly adult patients. AIDS 2000;14:1401-7.
73. Molez J. The historical question of acquired immunodeficiency syndrome in the 1960s in the Congo River basin area in relation to cryptococcal meningitis. Am J Trop Med Hyg 2001;58:273-6.
74. Dore GJ, Li Y, McDonald A, Kaldor JM. Spectrum of AIDS-defining illnesses in Australia, 1992 to 1998: Influence of country/region of birth. J Acquir Immune Defic Syndr Hum Retrovirol 2000;26:283-90.
75. Atkinson AJ, Bennett JE. Experience with a new skin test antigen prepared from Cryptococcus neoformans. Am Rev Respir Dis 1968;97:637-43.
76. Bennett JE. Cryptococcal skin test antigen: Preparation variables characterization. Infect Immunol 1981;32:373.
77. Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS 100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 1995;8:515-48.
78. Goldman D, Lee SC, Casadevall A. Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat. Infect Immunol 1994;62:4755-61.
79. Schwartz DA. Characterization of the biological activity of Cryptococcus infections in surgical pathology. Ann Clin Lab Sci 1988;18:388-97.
80. Levitz SM. Overview of host defenses in fungal infections. Clin Infect Dis 1992;14:S37-42.
81. Lipscomb MF. Lung defenses against opportunistic infections. Chest 1989;96:1393-9.
82. Lee SC, Dickson DW, Casadevall A. Pathology of cryptococcal meningoencephalitis: Analysis of 27 patients with pathogenetic implications. Hum Pathol 1996;27:839-47.
83. Goldman DL, Casadevall A, Cho Y, Lee SC. Cryptococcus neoformans meningitis in the rat. Lab Invest 1996;75:759-70.
84. Perfect JR, Lang SDR, Durack DT. Chronic cryptococcal meningitis: A new experimental model in rabbits. Am J Pathol 1980;101:177-94.
85. Aguirre K, Havell EA, Gibson GW, Johnson LL. Role of tumor necrosis factor and gamma interferon in acquired resistance to Cryptococcus neoformans in the central nervous system of mice. Infect Immunol 1995;63:1725-31.
86. Kawakami K, Tohyama M, Teruya K. Contribution of interferon-gamma in protecting mice during pulmonary and disseminated infection with Cryptococcus neoformans. FEMS Immunol Med Microbiol 1996;13:133-40.
87. Levitz SM. Macrophage-Cryptococcus interactions. In: Zwilling BS, Eisenstein TK, editors. Macrophage-Pathogen Interactions. New York: Marcel Dekker; 1994. p. 533.
88. Goldman D, Cho Y, Zhao ML. Expression of inducible nitric oxide synthase in rat pulmonary Cryptococcus neoformans granulomas. Am J Pathol 1996;148:1275-82.
89. Goldman DL, Lee SC, Mednic AJ. Persistent Cryptococcus neoformans infection in the rat is associated with intracellular parasitism, decreased inducible nitric oxide synthase expression and altered antibody responsiveness. Infect Immunol 2000;68:832-8.
90. Huffnagle GB, Strieter RM, McNeil LK. Macrophage inflammatory protein-1 alpha (MIP-alpha) is required for the efferent phase of pulmonary cell-mediated immunity to a Cryptococcus neoformans infection. J Immunol 1997;159:318-27.
91. Levitz SM, DiBenedetto DJ. Paradoxical role of capsule in murine bronchoalveolar macrophage-mediated killing of Cryptococcus neoformans. J Immunol 1989;142:659-65.
92. Huffnagle GB, Traynor TR, McDonald RA. Leukocyte recruitment during pulmonary Cryptococcus neoformans infection. Immunopharmacology 2000;48:231-6.
93. Vecchiarelli A. Cytokines and costimulatory molecules: Positive and negative regulation of the immune response to Cryptococcus neoformans. Arch Immunol Ther Exp 2000; 48:465-72.
94. + T cells cause multinucleated giant cells to form around Cryptococcus neoformans and confine the yeast within the primary site of infection in the respiratory tract. J Exp Med 1992;175:1685-95.
95. Casadevall A. Antibody immunity and invasive fungal infections. Infect Immunol 1995;63:4211-8.
96. Dromer F, Charreire J, Contrepois A, Carbon C, Yeni P. Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect Immunol 1987;55:749-52.
97. Sanford JE, Lupan DM, Schlageter AM, Kozel TR. Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide. Infect Immunol 1990;58:1919-23.
98. Mukherjee J, Sharff MD, Casadevall A. Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect Immunol 1992;60:4534-41.
99. Fleuridor R, Zhong Z, Pirofski L-A. A human IgM monoclonal antibody prolongs survival of mice with lethal cryptococcosis. J Infect Dis 1998;178:1213-6.
100. Devi SJN. Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model. Vaccine 1996;14:841-2.
101. Vecchiarelli A, Casadevall A. Antibody-mediated effects against Cryptococcus neoformans: Evidence for interdependency and collaboration between humoral and cellular immunity. Res Immunol 1998;149:321-33.
102. Rodriques ML, Travassos LR, Miranda KR. Human antibodies against a purified glucosylceramide from Cryptococcus neoformans inhibit cell budding and fungal growth. Infect Immunol 2000;68:7049-60.
103. Rosas AL, Nosanchuk JD, Casadevall A. Passive immunization with melanin-binding monoclonal antibodies prolongs survival in mice with lethal Cryptococcus neoformans infection. Infect Immunol 2001;69:3410-12.
104. Fleuridor R, Lyles RH, Pirofski L. Quantitative and qualitative differences in the serum antibody profiles of human immunodeficiency virus-infected persons with and without Cryptococcus neoformans meningitis. J Infect Dis 1999;180:1526-35.
105. Goldman DL, Fries BC, Franzot SP, Montella L, Casadevall A. Phenotypic switching in the human pathogenic fungus, Cryptococcus neoformans, is associated with changes in virulence and pulmonary inflammatory response in rodents. Proc Natl Acad Sci USA 1998;95:14967-72.
106. Gutierrez F, Fu YS, Lurie H. Cryptococcosis histologically resembling histoplasmosis: A light and electron microscopic study. Arch Pathol Lab Med 1975;99:347.
107. Feldmesser M, Kress Y, Novikoff P, Casadevall A. Cryptococcus neoformans is a facultative intracellular pathogen in murine pulmonary infection. Infect Immunol 2000;68:4225-37.
108. Feldmesser M, Tucker SC, Casadevall A. Intracellular parasitism of macrophages by Cryptococcus neoformans. Trends Microbiol 2001;9:273-8.
109. Murphy JW. Influence of cryptococcal antigens on cell-mediated immunity. Rev Infect Dis 1988;10:S432-5.
110. Murphy JW. Cryptococcal immunity and immunostimulation. Adv Exp Med Biol 1992;319:225-30.
111. Buchanan KL, Murphy JW. What makes Cryptococcus neoformans a pathogen? Emerg Infect Dis 1998;4:71-83.
112. Vecchiarelli A. Immunoregulation by capsular components of Cryptococcus neoformans. Med Mycol 2000;38:407-17.
113. Wong B, Perfect JR, Beggs S, Wright KA. Production of the hexitol D-mannitol by Cryptococcus neoformans in vitro and in rabbits with experimental meningitis. Infect Immunol 1990;58:1664-70.
114. Chaturvedi VP, Wong B, Newman SL. Oxidative killing of Cryptococcus neoformans by human neutrophils: Evidence that fungal mannitol protects by scavengering reactive oxygen intermediates. J Immunol 1996;156:3836-40.
115. Williamson PR. Biochemical and molecular characterization of the diphenol oxidase of Cryptococcus neoformans: Identification as a laccase. J Bacteriol 1994;176:656-64.
116. Nosanchuk JD, Rosas AL, Lee SC. Melanisation of Cryptococcus neoformans in human brain tissue. Lancet 2000;355:2049-50.
117. Rosas AL, Nosanchuk JD, Feldmesser M. Synthesis of polymerized melanin by Cryptococcus neoformans in infected rodents. Infect Immunol 2000;68:2845-53.
118. Casadevall A, Rosas AL, Nosanchuk JD. Melanin and virulence in Cryptococcus neoformans. Curr Opin Microbiol 2000;4:354-8.
119. Huffnagle GB, Chen GH, Curtis JL, McDonald RA, Streiter RM, Toews GB. Down-regulation of the different phase of T cell-mediated pulmonary inflammation and immunity by a high melanin-producing strain of Cryptococcus neoformans. J Immunol 1995;155:3507-16.
120. Noverr MC, Phare SM, Toews GB. Pathogenic yeasts Cryptococcus neoformans and Candida albicans produce immunomodulatory prostaglandins. Infect Immunol 2001;69:2957-63.
121. Pappas PG, Perfect JR, Cloud GA, Larsen RA, Pankey GA, Lancaster DJ, et al. Cryptococcosis in HIV-negative patients in the era of effective azole therapy. Clin Infect Dis 2001;33:690-9.
122. Perfect JR. Cryptococcosis. Infect Dis Clin North Am 1989;3:77-102.
123. Duperval R, Hermans PE, Brewer NS, Roberts GD. Cryptococcosis, with emphasis on the significance of isolation of Cryptococcus neoformans from the respiratory tract. Chest 1977;72:13-9.
124. Cameron ML, Bartlett JA, Gallis HA, Waskin HA. Manifestations of pulmonary cryptococcosis in patients with acquired immunodeficiency syndrome. Rev Infect Dis 1991;13:64-7.
125. Campbell GD. Primary pulmonary cryptococcosis. Am Rev Respir Dis 1966;94:236-43.
126. Warr W, Bates JH, Stone A. The spectrum of pulmonary cryptococcosis. Ann Intern Med 1968;69:1109-16.
127. Gerstenhaber BJ, Weiner B, Morecki R, Bernstein R, Luftschein S. "Allergic" cryptococcal pneumonia. Lung 1977;154:195-9.
128. Mitchell DH, Sorrell TC. Pancoast's syndrome due to pulmonary infection with Cryptococcus neoformans variety gatti. Clin Infect Dis 1992;14:1142-4.
129. Cary CF, Mueller L, Fotopoulos CL, Dall L. Bronchitis obliterans - Organizing pneumonia associated with Cryptococcus neoformans infection. Rev Infect Dis 1991;13:1253-4.
130. Lehmann PF, Morgan RJ, Freimer EH. Infection with Cryptococcus neoformans var. gattii leading to a pulmonary cryptococcoma and meningitis. J Infect 1984;9:301-6.
131. Menon A, Rajamani R. Giant "cryptococcomas" of the lung. Br J Dis Chest 1976;70:269-72.
132. Corpe RF, Parr LH. Pulmonary torulosis complicating pulmonary tuberculosis treated by resection. J Thorac Cardiovasc Surg 1953;27:392-8.
133. Kahn FW, England DM, Jones JM. Solitary pulmonary nodule due to Cryptococcus neoformans and Mycobacterium tuberculosis. Am J Med 1985;78:677-81.
134. Riley E, Cahan WG. Pulmonary cryptocococcis followed by pulmonary tuberculosis: A case report. Am Rev Respir Dis 1972;106:594-9.
135. Dalgleish AG. Concurrent hydatid disease and cryptococcosis in a 16-year-old girl. Med J Aust 1981;2:144-5.
136. Feigin DS. Pulmonary cryptococcosis: Radiologic-pathologic correlates of its three forms. AJR Am J Roentgenol 1983;141:1263-72.
137. Kerkering TM, Duma RJ, Shadomy S. The evolution of pulmonary cryptococcosis: Clinical implications from a study of 41 patients with and without compromising host factors. Ann Intern Med 1981;94:611-6.
138. Henson DJ, Hill AR. Cryptococcal pneumonia: A fulminant presentation. Am J Med 1984;228:221.
139. Kent TH, Layton JM. Massive pulmonary cryptococcosis. Am J Clin Pathol 1962;38: 596-604.
140. Murray RJ, Becker P, Furth P, Criner GJ. Recovery from cryptococcemia and the adult respiratory distress syndrome in the acquired immunodeficiency syndrome. Chest 1988;93:1304-7.
141. Woods ML, MacGinley R, Eisen DP, Allworth AM. HIV combination therapy: Partial immune restitution unmasking latent cryptococcal infection. AIDS 1998;12:1491-4.
142. Mitchell DH, Sorrell TC, Allworth AM, Heath CH, McGregor AR, Papahaoum K, et al. Cryptococcal disease of the CNS in immunocompetent hosts: Influence of cryptococcal variety on clinical manifestations and outcome. Clin Infect Dis 1995;20:611-6.
143. Speed B, Dunt D. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis 1995;21:28-34.
144. Cauley LK, Murphy JW. Response of congenital athymic (nude) and phenotypically normal mice to Cryptococcus neoformans infection. Infect Immunol 1979;23:644-51.
145. Littman ML, Zimmerman LE. Cryptococcosis, torulosis or European blastomycosis. In: Anonymous. Cryptococcosis. New York: Grune and Stratton; 1956. p. 38.
146. Sarosi GA, Parker JD, Doto IL, Tosh FE. Amphotericin B in cryptococcal meningitis: Long-term results of treatment. Ann Intern Med 1969;71:1079-87.
147. Schupbach CW, Wheeler CE, Briggaman RA. Cutaneous manifestations of disseminated cryptococcosis. Arch Dermatol 1976;112:1734-44.
148. Borton LK, Wintroub BU. Disseminated cryptococcosis presenting as herpetiform lesions in a homosexual man with acquired immunodeficiency syndrome. J Am Acad Dermatol 1984;10:387-90.
149. Concus AP, Helfand RF, Imber MJ, Lerner SA, Sharpe RJ. Cutaneous cryptococcosis mimicking Molluscum contagiosum in a patient with AIDS. J Infect Dis 1988;158:897-8.
150. Pema K, Diaz J, Guerra LG, Nabhan D, Verghese A. Disseminated cutaneous cryptococcosis: Comparison of clinical manifestations in the pre-AIDS and AIDS eras. Arch Intern Med 1994;154:1032-4.
151. Gauder JP. Cryptococcal cellulitis. JAMA 1977;237:672-3.
152. Mayers DL, Martone WJ, Mandell GL. Cutaneous cryptococcosis mimicking gram-positive cellulitis in a renal transplant patient. South Med J 1981;74:1032.
153. Casadevall AJ, Mukherjee J, Ruong R, Perfect JR. Management of Cryptococcus neoformans contaminated needle injuries. Clin Infect Dis 1994;19:951-3.
154. Glaser JB, Garden A. Inoculation of cryptococcosis without transmission of the acquired immunodeficiency syndrome. N Engl J Med 1985;313:264.
155. Pierard GE, Pierard-Franchimont C, Estrada JA, Rurangirwa A, Dosal FL. Cutaneous mixed infections in AIDS. Am J Dermatopathol 1990;12:63-6.
156. Odom A, Del Poeta M, Perfect J, Heitman J. The immunosuppressant FK506 and its non-immunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. Antimicrob Agents Chemother 1997;41:156-61.
157. Braman RT. Cryptococcosis (Torulopsis) of prostate. Urology 1981:17:284-6.
158. Plunkett JM, Turner BI, Tallent MB. Cryptococcal septicemia associated with urologic instrumentation in a renal allograft recipient. J Urol 1981;125:241-2.
159. Larsen RA, Bozzette S, McCutchan A, Chiu J, Leal MA, Richman DD. Persistent Cryptococcus neoformans infection of the prostate after successful treatment of meningitis. Ann Intern Med 1989;111:125-8.
160. Staib F, Seibold M, L'age M, Heise W, Skorde J, Grosse G, et al. Cryptococcus neoformans in the seminal fluid of an AIDS patient: A contribution to the clinical course of cryptococcosis. Mycoses 1989;32:171-80.
161. Perfect JR, Seaworth B. Penile cryptococcosis with a review of mycotic infections of the penis. Urology 1985;25:528-31.
162. Blocker KS, Weeks JA, Noble RC. Cutaneous cryptococcal infection presenting as valvular lesion. Genitourin Med 1987;63:341-3.
163. Okun E, Butler WT. Ophthalmologic complications of cryptococcal meningitis. Arch Ophthalmol 1964;71:52-7.
164. Nelson MR, Bower M, Smith D, Reed C, Shanson D, Gazzard B. The value of serum cryptococcal antigen in the diagnosis of cryptococcal infection in patients infected with the human immunodeficiency virus. J Infect Dis 1990;21:175-81.
165. Crump JR, Elner SG, Elner VM, Kauffman CA. Cryptococcal endophthalmitis: Case report and review. Clin Infect Dis 1992;14:1069-73.
166. Doft BH, Curtin VT. Combined ocular infection with cytomegalovirus and cryptococcosis. Arch Ophthalmol 1982;100:1800-3.
167. Denning DW, Armstrong RW, Fishman M, Stevens DA. Endophthalmitis in a patient with disseminated cryptococcosis and AIDS who was treated with itraconazole. Rev Infect Dis 1991;13:1126-30.
168. Johnston SR, Corbett EL, Foster O, Ash S, Cohen J. Raised intracranial pressure and visual complications in AIDs patients with cryptococcal meningitis. J Infect 1992;24:185-9.
169. Rex JH, Larsen RA, Dismukes WE, Cloud GA, Bennett JA. Catastrophic visceral loss due to Cryptococcus neoformans meningitis. Medicine (Baltimore) 1993;72:207-24.
170. Perry HD, Donnenfeld ED. Cryptococcal keratitis after keratoplasty. Am J Ophthalmol 1990;110:320-1.
171. Behrman RE, Masci JR, Nicholas P. Cryptococcal skeletal infections: Case report and review. Rev Infect Dis 1990;12:181-90.
172. Yinnon AM, Solages A, Treanor JJ. Cryptococcal peritonitis: Report of a case developing during continuous ambulatory peritoneal dialysis and review of the literature. Clin Infect Dis 1993;17:736-41.
173. Bottone EJ, Toma M, Johansson BE, Wormser GP. Capsule-deficient Cryptococcus neoformans in AIDS patients. Lancet 1985;2:553.
174. Yagupsky P, Menegus MA. Cumulative positivity rates of multiple blood cultures for Mycobacterium avium intracellulare and Cryptococcus neoformans in patients with the acquired immunodeficiency syndrome. Arch Pathol Lab Med 1990;114:923-5.
175. Chaskes S, Tyndall RL. Pigment production by Cryptococcus neoformans and other Cryptococcus species from aminophenols and diaminobenzenes. J Clin Microbiol 1978;7:146-52.
176. Kwon-Chung KJ, Bennett JE. Cryptococcosis. Anonymous. Medical Mycology. Philadelphia: Lea & Febiger; 1992. p. 397.
177. Staib F. Cryptococcus neoformans und Guizotia abyssinica (Syn. G. oleifera) Farbreaktion fur C. neoformans. ZentralblHyg Umweltmed 1962;148:466-75.
178. el-Zaatari M, Pasarell L, McGinnis MR, Buckner J, Land GA, Salkin IF. Evaluation of the updated Vitek yeast identification data base. J Clin Microbiol 1990;28:1938-41.
179. St. Germain G, Beauchesne D. Evaluation of the microscan rapid yeast identification panel. J Clin Microbiol 1991;29:2296-9.
180. Huffnagle KE, Gander RM. Evaluation of Gen-probe's Histoplasma capsulatum and Cryptococcus neoformans ACCU probes. J Clin Microbiol 1993;31:419-21.
181. Mitchell TG, Freedman EZ, White TJ, Taylor JW. Unique oligonucleotide primers in PCR for identification of Cryptococcus neoformans. J Clin Microbiol 1994;32:253-5.
182. Kwon-Chung KJ, Polacheck I, Bennett JE. Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var gattii (serotypes B and C). Ann Intern Med 1985;103:533-8.
183. Ikeda R, Shinoda R, Fukazawa Y, Kaufman L. Antigenic characterization of Cryptococcus neoformans serotypes and its application of serotyping of clinical isolates. J Clin Microbiol 1982;16:22-9.
184. Kabasawa K, Itagaki H, Ikeda R, Shinoda T, Kagaya K, Fukazawa Y. Evaluation of a new method for identification of Cryptococcus neoformans which uses serologic tests aided by selected biological tests. J Clin Microbiol 1991;29:2873-6.
185. Brandt ME, Bragg SL, Pinner RW. Multilocus enzyme typing of Cryptococcus neoformans. J Clin Microbiol 1993;31:2819-23.
186. Crampin AC, Matthews RC, Hall D, Evans EGV. PCR fingerprinting Cryptococcus neoformans by random amplification of polymorphic DNA. J Med Vet Mycol 1993;31:463-5.
187. Spitzer ED, Spitzer SG. Use of a dispersed repetitive DNA element to distinguish clinical isolates of Cryptococcus neoformans. J Clin Microbiol 1992;30:1094-7.
188. Varma A, Kwon-Chung KJ. DNA probe for strain typing of Cryptococcus neoformans. J Clin Microbiol 1992;30:2960-7.
189. Campbell CK, Payne AL, Teall AJ, Brownell A, Mackenzie DWR. Cryptococcal latex antigen test positive in patient with Trichosporon beigelii infection. Lancet 1985;2:43.
190. Chanock SJ, Toltzis P, Wilson C. Cross-reactivity between Stomatococcus mucilaginosus and latex agglutination for cryptococcal antigen. Lancet 1993;342:1119-20.
191. McManus EJ, Jones JM. Detection of a Trichosporon beigelii antigen cross-reactive with Cryptococcus neoformans capsular polysaccharides in serum from a patient with disseminated Trichosporon infection. J Clin Microbiol 1985;21:681-5.
192. Baughman RP, Rhodes JC, Dohn MN, Henderson H, Frame PT. Detection of cryptococcal antigen in bronchoalveolar lavage fluid: A prospective study of diagnostic utility. Am Rev Respir Dis 1992;145:1226-9.
193. Desmet P, Kayembe KD, DeVroey C. The value of cryptococcal serum antigen screening among HIV positive AIDS patients in Kinshasa, Zaire. AIDS 1989;3:77-8.
194. Hunt Jr. KK, Enquist RW, Bowen TE. Multiple pulmonary nodules with central cavitation. Chest 1976;69:529-30.
195. Khoury MB, Godwin JD, Ravin CE, Gallis HA, Halvorsen RA, Putnam CE. Thoracic cryptococcosis: Immunologic competence and radiologic appearance. AJR Am J Roentgenol 1984;141:893-6.
196. McAllister CK, Davis Jr. CE, Ognibene AJ, Carpenter JL. Cryptococcal pleuropulmonary disease: infection of the pleural fluid in the absence of disseminated cryptococcosis. Case report. Mil Med 1984;149:684-6.
197. Young EJ, Hirsh DD, Fainstein V, Williams TW. Pleural effusions due to Cryptococcus neoformans: A review of the literature and report of two cases with cryptococcal antigen determinations. Am Rev Respir Dis 1980;121:743-6.
198. Zlupko GM, Fochler FJ, Goldschmidt ZH. Pulmonary cryptococcosis presenting with multiple pulmonary nodules. Chest 1980;77:575.
199. Clark RA, Greer DL, Valainis GT, Hyslop NE. Cryptococcus neoformans pulmonary infection in HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1990;3:480-5.
200. Miller WT, Edelman JM. Cryptococcal pulmonary infection in patients with AIDS: Radiographic appearance. Radiology 1990;175:725-8.
201. Cornell SH, Jacoby CG. The varied computed tomographic appearance of intracranial cryptococcosis. Radiology 1982;143:703-7.
202. Tan CT, Kuan BB. Cryptococcus meningitis, clinical-CT scan considerations. Neuroradiology 1987;29:43-6.
203. Long JA, Herdt JR, DiChiro G, Cramer HR. Cerebral mass lesions in torulosis demonstrated by computer tomography. J Comput Assist Tomogr 1980;4:766-9.
204. Poprich MJ, Arthur RH, Helmer E. CT of intracranial cryptococcosis. AJR Am J Roentgenol 1990;154:603-6.
205. Wehn SM, Heinz R, Burger PC. Dilated Virchow-Robin spaces in cryptococcal meningitis associated with AIDS: CT and MR findings. J Comput Assist Tomogr 1989;13:756-62.
206. Ingram CW, Haywood HB, Morris VM, Allen RL, Perfect JR. Cryptococcal ventricular peritoneal shunt infection: Clinical and epidemiological evaluation of two closely associated cases. Infect Immunol 1993;14:719-22.
207. Hospenthal D, Bennett JE. Persistence of cryptococcomas on neuroimaging. Clin Infect Dis 2000;31:1303-6.
208. Saag MS, Graybill JR, Larsen RA, Pappas PG, Perfect JR, Powderly WG, et al. Practice guidelines for the management of cryptococcal disease. Infectious Disease Society of America. Clin Infect Dis 2000;30:710-8.
209. Espinel-Ingroff A, Kish Jr. CW, Kerkering TM, Fromtling RA, Bartizal K. Galgiani JN, et al. Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol 1992;30:3138-45.
210. Fromtling RA, Galgiani JN, Pfaller MA, Espinel-Ingroff A, Bartizal KF, Bartlett MS, et al. Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts. Antimicrob Agents Chemother 1993;37:39-45.
211. Ghannoun MA, Ibrahim AS, Fu Y, Shafig MC, Edwards JE, Criddle RS. Susceptibility testing of Cryptococcus neoformans: A microdilution technique. J Clin Microbiol 1992;30:2881-6.
212. Shadomy S, Pfaller MA. Laboratory studies with antifungal agents: Susceptibility tests and quantitation in body fluids. In: Balows A, Hausler Jr. WJ, Herrmann KL, Isenberg HD, Shadomy HJ, editors. Manual of Clinical Microbiology. 5th Edition. Washington: American Society for Microbiology; 1991. p. 1173.
213. Polak A. 5-Flurocytosine and its combination with other antifungal agents. In: Yamaguchi H, Kobayashi G, Takahashi H, editors. Recent Progress in Antifungal Chemotherapy. New York: Marcel-Dekker; 1992. p. 77.
214. Utz JP, Shadomy S, McGehee RF. 5-Flucytosine: Experience in patients with pulmonary and other forms of cryptococcosis. Am Rev Respir Dis 1969;99:975.
215. Albert MM, Graybill JR, Rinaldi MG. Treatment of murine cryptococcal meningitis with an SCH 39304-amphotericin B combination. Antimicrob Agents Chemother 1991;35:1721-5.
216. Bodenhoff J. Development of strains of Cryptococcus neoformans resistant to nystatin, amphotericin B, trichomycin, and polymyxin B. Acta Pathol Microbiol Scand 1968; 73:572-82.
217. Perfect JR, Cox GM. Drug resistance in Cryptococcus neoformans. Drug Resistance Updates 1999;2:259-69.
218. Spitzer ED, Spitzer SG, Freundlich LF, Casadevall A. Persistence of initial infection in recurrent Cryptococcus neoformans meningitis. Lancet 1993;341:595-6.
219. Casadevall A, Spitzer ED, Webb D, Rinaldi MG. Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole. Antimicrob Agents Chemother 1993;37:1383-6.
220. Dupouy-Camet J, Paugam A, Di Donato C, Viguie C, Vicens I, Volle PJ, et al. Resistance to fluconazole in hospitalized patients: Concordance between Candida albicans resistance in vitro and therapeutic failure [letter]. Presse Med 1991;20:1341.
221. Valez JD, Allendoerfer R, Luther M, Rinaldi MG, Graybill JR. Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis. J Infect Dis 1993;168:508-10.
222. Burgess DS, Hastings RW. A comparison of dynamic characteristics of fluconazole, itraconazole, and amphotericin B against Cryptococcus neoformans using time-kill methodology. Diagn Microbiol Infect Dis 2000;38:87-93.
223. Aller AI, Martin-Manzuelos E, Lozano F, Gomez-Mateos J, Steele-Moore L, Holloway WJ, et al. Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob Agents Chemother 2000;44:1544-8.
224. Xu J, Dnyewu C, Yoell HJ, Ali RY, Vilgalys RJ, Mitchell TG. Dynamic and heterogenous mutations to fluconazole resistance in Cryptococcus neoformans. Antimicrob Agents Chemother 2001;45:420-7.
225. Diamond DM, Bauer M, Daniel BE, Leal MA, Johnson D, Williams BK, et al. Amphotericin B colloidal dispension combined with flucytosine with or without fluconazole for treatment of murine cryptococcal meningitis. Antimicrob Agents Chemother 1998;42:528-33.
226. Medoff G, Kobyashi GS, Kwan CN, Schlessinger D, Venkov P. Potentiation of rifampicin and 5-fluorocytosine as antifungal antibiotics by amphotericin B. Proc Natl Acad Sci U S A 1972;69:196-9.
227. Polak A, Schroder HJ, Wall M. Combination therapy of experimental candidiasis, cryptococcosis, and aspergillosis in mice. Chemotherapy 1982;28:461-79.
228. Bennett JE, Dismukes W, Duma RJ, Medoff G, Sande MA, Gallis H, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 1979;301:126-31.
229. Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco MH, Sharkey PK, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992;326:83-9.
230. Robinson PA, Bauer M, Leal MA, Evans SG, Holton PD, Diamond DA, et al. Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Clin Infect Dis 1999;28:82-92.
231. deLalla F, Pellizzer G, Vaglia A. Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: Reliability of relatively high doses administered over a relatively short period. Clin Infect Dis 1995;20:263-6.
232. Hamil RJ, Sobel J, El-Sadr W, Johnson P, Graybill JR, Javaly K, et al. Randodmized double-blind trial of ambisome and amphotericin B in acute cryptococcal meningitis in AIDS patients [abstract 1161]. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 26-29, 1999.
233. Sharkey PK, Graybill JR, Johnson ES, Hausroth SG, Pollard RB, Kolokathis A, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996;22:315-21.
234. Utz JP, Shadomy S, McGehee RF, Flucytosine. N Engl J Med 1972;286:777-8.
235. Utz JP, Garrigues IL, Sande MA, Warner JF, Mandell GL, McGhee RF, et al. Therapy of cryptococcosis with a combination of flucytosine and amphotericin B. J Infect Dis 1975;132:368-73.
236. Dismukes WE, Cloud G, Gallis HA, Kerkering TM, Medoff G, Craven PL, et al. Nat'l Institute of Allergy and Infectious Diseases Mycoses Study Group. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 1987;317:334-41.
237. Larsen RA, Leal MAE, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. Ann Intern Med 1990;113:183-7.
238. DeGans J, Portegies P, Tiessens G. Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis. AIDS 1992;6:185-90.
239. Saag MS, Cloud GA, Graybill JR, Sobel JD, Tuazon CV, Johnson PC, et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis 1999;28:291-6.
240. Witt MD, Lewis RJ, Larsen RA, Milefchik EN, Leal M, Haubrich RH, et al. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: The role of antifungal susceptibility testing. Clin Infect Dis 1996;22:322-8.
241. van der Horst C, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med 1997;337:15-21.
242. Ding JC, Bauer M, Diamond DM, Leal MA, Johnson D, Williams BK, et al. Effect of severity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryptococcal meningitis. Antimicrob Agents Chemother 1997;41:1589-93.
243. Lortholary O, Nicholas M, Soreda S, Improvisi L, Ronin O, Petitjean O, et al. Fluconazole with or without dexamethasone for experimental cryptococcosis: Impact of treatment timing. J Antimicrob Chemother 1999;43:817-24.
244. Berry AJ, Rinaldi MG, Graybill JR. Use of high dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS. Antimicrob Agents Chemother 1992;36:690-2.
245. Allendoerfer R, Marquis AJ, Rinaldi MG, Graybill JR. Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis. Antimicrob Agents Chemother 1991;35:726-9.
246. Larsen RA, Bozzette SA, Jones BE, Haghighat D, Leal MA, Forthal D, et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994;19:741-5.
247. Bozzette SA, Larsen RA, Chin J. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. N Engl J Med 1991;324:580-4.
248. Powderly WG, Saag MS, Cloud GA, Robinson P, Meyer R, Jacobson JM, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992;326:793-8.
249. Denning DW, Tucker RM, Hanson LH, Hamilton JR, Stevens DA. Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch Intern Med 1989;149:2301-8.
250. Viviani MA, Tortorano AM, Langer M, Alma-viva M, Negri E, Christina S, et al. Experience with itraconazole in cryptococcosis and aspergillosis. J Infect 1989;18:151-65.
251. Viviani MA, Tortorano AM, Giani PC, Arici C, Goglio A, Crocchiolo P, et al. Itraconazole for cryptococcal infection in the acquired immunodeficiency syndrome [letter]. Ann Intern Med 1987;106:166.
252. Sung JP, Campbell GD, Grendahl JG. Miconazole therapy for fungal meningitis. Arch Intern Med 1978;35:443-7.
253. Weinstein L, Irving J. Successful treatment of cerebral cryptococcoma and meningitis with miconazole. Ann Intern Med 1980;93:569-71.
254. Graybill JR, Levine HB. Successful treatment of cryptococcal meningitis with intraventricular miconazole. Ann Intern Med 1978;138:814-6.
255. Perfect JR, Durack DT, Hamilton JD, Gallis HA. Failure of ketoconazole in cryptococcal meningitis. JAMA 1982;247:3349-51.
256. Dismukes WE, Stamm AM, Garybill JR, Craven PC, Stevens DA, Stiller RL, et al. Treatment of systemic mycoses with ketoconazole: Emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases Collaborative Antifungal Study. Ann Intern Med 1983;98:13-20.
257. Yildiran ST, Saracli MA, Fothergill AW, Rinaldi MG. In vitro susceptibility of environmental Cryptococcus neoformans variety neoformans isolates from Turkey to six antifungal agents including SCH 56592 and voriconazole. Eur J Clin Microbiol 2000;19:317-9.
258. Perfect JR, Cox GM, Dodge RK, Schell WA. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother 1996;40:1910-3.
259. Perfect JR, Irja L, Gonzalez-Ruiz A. Voriconazole for treatment of resistant and rare fungal pathogens [abstract 303]. Presented at the 38th Infectious Disease Society Meeting, New Orleans, LA, September 7-10, 2000.
260. Hachem R, Raad II, Affie CM, Negroni R, Graybill J, Hadley MN, et al. An open, noncomparative multicenter study to evaluate efficacy and safety of posaconazole in the treatment of invasive fungal infections refractory to or intolerant to standard therapy [abstract 1109]. Presented at the 40th Interscience Conference on Antimicrobial Agents Chemotherapy, Toronto, Ontario, September 17-20, 2000.
261. Dromer F, Mathoulin S, Dupont B, Brugiere O, Letenneur L. Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: Retrospective analysis of 83 cases. Clin Infect Dis 1996;22(suppl 2):s154-60.
262. Yamaguchi H, Ikemoto H, Watanabe K, Ito A, Hara K, Kohno S. Fluconazole monotherapy for cryptococcosis in non-AIDS patients. Eur J Clin Microbiol Infect Dis 1996;15:787-92.
263. Fujita NK, Reynard M, Sapico FL, Guze LB, Edwards Jr. JE. Cryptococcal intracerebral mass lesions. Ann Intern Med 1981;94:382-8.
264. DeWit S, Goosens H, Weerts D. Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. Lancet 1989;1:746-8.
265. Aberg JA, Price RW, Heeren DM. Discontinuation of antifungal therapy for cryptococcosis following immunologic response to antiretroviral therapy [abstract 250]. Presented at the 7th International Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, January 30-February 2, 2000.
266. Martinez E, Garcia-Viejo MA, Marcos MA. Discontinuation of secondary prophylaxis for cryptococcal meningitis in HIV-infected patients responding to highly active antiretroviral therapy. AIDS 2000;14:2615.
267. Mussini C, Cossarizza A, Pezzotti P. Discontinuation or continuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with HAART [abstract 546]. Presented at the 8th Conference on Retroviruses and Opportunistic Infections; Chicago, IL, February 4-8, 2001.
268. Denning DW, Armstrong RW, Lewis BH, Stevens DA. Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome. Am J Med 1991;91:267-72.
269. Graybill JR, Sobel J, Saag M, van der Horst C, Powderly W, Cloud G, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. Clin Infect Dis 2000;30:47-54.
270. Powderly WG, Cloud GA, Dismukes WE, Saag MS. Measurement of cryptococcal antigen in serum and cerebrospinal fluid: Value in the management of AIDS-associated cryptococcal meningitis. Clin Infect Dis 1994;18:789-92.
271. Feldmesser M, Harris C, Reichberg S, Khan S, Casadevall A. Serum cryptococcal antigen in patients with AIDS. Clin Infect Dis 1996;23:827-30.
272. Torres R, Villarreal C, Robles M, Aparicio P, Cano P. Comparative study with two treatments for Cryptococcus neoformans meningitis in patients with AIDS: Granulocyte-macrophage colony-stimulating factor (GM-CSF) and amphotericin B vs amphotericin B alone: Preliminary report [abstract]. Presented at the 2nd International Conference on Cryptococcus and Cryptococcosis. Milan, Italy, September 19-23, 1993.
273. Clemons KV, Lutz JE, Stevens DA. Efficacy of recombinant gamma interferon for treatment of systemic cryptococcosis in SCID mice. Antimicrob Agents Chemother 2001;45:686-9.
274. Mukherjee J, Pirofski LA, Scharff MD, Casadevall A. Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection. Proc Natl Acad Sci U S A 1993;90:3636-40.
275. Mukherjee J, Zuckier LS, Scharff MD, Casadevall A. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B. Antimicrob Agents Chemother 1994;38:580-7.
276. Dromer F, Charreire J. Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: Study during murine cryptococcosis and mechanisms of action. J Infect Dis 1991;163:1114-20.
277. White M, Cirrincione C, Blevins A, Armstrong D. Cryptococcal meningitis with AIDS and patients with neoplastic disease. J Infect Dis 1992;165:960-6.
278. Diamond RD, Bennett JE. Prognostic factors in cryptococcal meningitis: A study of 111 cases. Ann Intern Med 1974;80:176-81.
279. Nightingale SD, Cal SX, Peterson DM, Loss SD, Gamble BA, Watson DA, et al. Primary prophylaxis with fluconazole against systemic fungal infections in HIV-positive patients. AIDS 1992;6:191-4.
280. Devi SJ, Scheerson R, Egan W, Ulrich TJ, Bryla D, Robbins JB, et al. Cryptococcus neoformans serotype A glucuronoxylomannan protein conjugate vaccines: Synthesis, characterization, and immunogenicity. Infect Immunol 1991;59:3700-7.